Difference between revisions of "Glasdegib (Daurismo)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/hedgehog-inhibitor-pf-04449913 NCI Drug Dictionary]: An oral...") |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/21/2018: Initial FDA approval for use "in combination with low-dose [[Cytarabine (Cytosar)|cytarabine]] (LDAC), for newly-diagnosed [[Acute myeloid leukemia|acute myeloid leukemia (AML)]] in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy." | *11/21/2018: Initial FDA approval for use "in combination with low-dose [[Cytarabine (Cytosar)|cytarabine]] (LDAC), for newly-diagnosed [[Acute myeloid leukemia|acute myeloid leukemia (AML)]] in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy." | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf Glasdegib (Daurismo) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf Glasdegib (Daurismo) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' PF-04449913 | *'''Code name:''' PF-04449913 | ||
*'''Brand name:''' Daurismo | *'''Brand name:''' Daurismo | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 11:11, 4 April 2021
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 11/21/2018: Initial FDA approval for use "in combination with low-dose cytarabine (LDAC), for newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy."
Patient Drug Information
Also known as
- Code name: PF-04449913
- Brand name: Daurismo